Anti-Nogo-A antibodies and methods of making and using thereof
AssigneeNovaGo Therapeutics AG
InventorsBenoit Combaluzier, Eduardo Paulo Morawski Vianna, Michael Andreas Maurer
Life of this patent
Estimating the term…
Abstract
Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.
Claims18
A recombinant monoclonal anti-Nogo-A antibody or an antigen-binding fragment thereof, comprising a variable heavy chain (VH) and a variable light chain (VL), wherein
- (a) the VH comprises a VH complementary determining region 1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:
- 3, a VH complementary determining region 2 (VH-CDR2) comprising the amino acid sequence of SEQ ID NO:
- 4, and a VH complementary determining region 3 (VH-CDR3) comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- (b) the VL comprises a VL complementary determining region 1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:
- 8, a VL complementary determining region 2 (VL-CDR2) comprising the amino acid sequence of SEQ ID NO:
- 9, and a VL complementary determining region 3 (VL-CDR3) comprising the amino acid sequence of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.